Hormonal and barrier contraceptive choices have undergone unprecedented expansion over the past decade. Oral contraceptives have been joined by products with alternative hormone delivery systems, including transdermal, injectable, and intravaginal. In addition, the doses and chemical structures of the estrogen and progestin components have been altered to improve tolerability. Barrier methods continue to offer nonhormonal options with varied levels of protection from sexually transmitted infections. With the expansion of choices, consideration of individual needs is key to maximizing effectiveness and tolerability. Future advancements will continue to focus on individualized options as well as expanded male contraceptive devices.
2. Henshaw S. Unintended pregnancy in the United States . Fam Plann Perspect. 1998;30: 24-29, 46 .
3.
3. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices . Am J Obstet Gynecol. 1999;181: 1263-1269 .
4.
4. Hatcher R, Trussell J, Stewart F, et al. Contraceptive Technology. 17th ed. New York, NY: Ardent Media ; 1998.
5.
5. Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use. 2nd ed. Geneva, Switzerland: Reproductive Health and Research, World Health Organization ; 2000.
6.
6. Piccinino L, Mosher W. Trends in contraceptive use in the United States: 1982-1995 . Fam Plann Perspect. 1998:30: 4-10, 46 .
7.
7. Fisher W, Boroditsky R, Bridges M. The 1998 Canadian Contraceptive Study . Can J Hum Sex. 1999:8: 207-211 .
8.
8. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth . Fam Plann Perspect. 1999;31: 64-72, 93 .
9.
9. Rosenberg M, Waugh M. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons . Am J Obstet Gynecol. 1998;179: 577-582 .
10.
10. Endrikat J, Dusterberg B, Ruebig A, Gerlinger C, Strowitzki T. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study . Contraception. 1999;60: 269-274 .
11.
11. Hampton R. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho-TriCyclen Lo) with the oral contraceptive Loestrin Fe 1/20 . Contraception. 2001;63: 289-295 .
12.
12. Kaunitz A. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial . Contraception. 2000;61: 295-302 .
13.
13. Rosenberg M, Meyers A, Roy V. Efficacy, cycle control, and side effects of low-and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations . Contraception. 1999;60: 321-329 .
14.
14. Thorneycroft I. Update on androgenicity . Am J Obstet Gynecol. 1999;180: S288-S294 .
15.
15. Huber J, Foidart J, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone . Eur J Contracept Reprod Health Care. 2000;5: 25-34 .
16.
16. Parsey K, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen . Contraception. 2000;61: 105-111 .
17.
17. Foidart J, Wuttke W, Bouw G, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel . Eur J Contracept Reprod Health Care. 2000;5: 124-134 .
18.
18. Oelkers W, Foidart J, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineral-ocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism . J Clin Endocrinol Metab. 1995;80: 1816-1821 .
20. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Dusterberg B. Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene . Contraception. 2001;64: 99-105 .
22. Sulak P, Scow R, Preece C, Riggs M, Kuehl T. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms . Obstet Gynecol. 2000;95: 261-266 .
23.
23. Sulak P, Cressman B, Waldrop E, Holleman S, Kuehl T. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms . Obstet Gynecol. 1997;89: 179-183 .
24.
24. Sulak P, Kuehl T, Ortiz M, Shull B. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms . Am J Obstet Gynecol. 2002;186: 1142-1149 .
25.
25. Peterson L, Oakley D, Potter L, Darroch J. Women's efforts to prevent pregnancy: consistency of oral contraceptive use . Fam Plann Perspect. 1998;30: 19-23 .
26.
26. Rosenberg M, Waugh M, Burnhill M. Compliance, counseling, and satisfaction with oral contraceptives: a prospective evaluation . Fam Plann Perspect. 1998;30: 89-92, 104 .
28. Mulders T, Dieben T. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition . Fertil Steril. 2001;75: 865-870 .
29.
29. Bjarnadottir R, Tuppurainen M, Killick S. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol . Am J Obstet Gynecol. 2002;186: 389-395 .
30.
30. Roumen F, Apter D, Mulders T, Dieben T, Efficacy, tolerability, and acceptability or a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol . Hum Reprod. 2001;16: 469-475 .
32. Kaunitz A, Garceau R, Cromie M. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group . Contraception. 1999;60: 179-187 .
33.
33. Garceau R, Kaunitz A, Wajszczuk C. Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives . Contraception. 2000;62: 289-295 .
34.
34. Rahimy M, Ryan K. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women . Contraception. 1999;60: 189-200 .
35.
35. Shulman L, Oleen-Burkey M, Willke R. Patient acceptability and satisfaction with Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) . Contraception. 1999;60: 215-222 .
38. Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions . Fertil Steril. 2002;77(2 suppl 2): S32-S35 .
39.
39. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive . JAMA. 2001;285(18): 2347-2354 .
40.
40. Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW. Efficacy and safety of a transdermal contraceptive system . Obstet Gynecol. 2001;98(5 pt 1): 799-805 .
41.
41. Zieman M, Guillebaud J, Weisberg E, Shangold G, Fisher A, Creasy G. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data . Fertil Steril. 2002;77(2 suppl 2): S13-S18 .
43. Harel Z, Biro F, Kolar L, Rauh J. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant . J Adolesc Health. 1996;19: 118-123 .
44.
44. Hollander D. Menstrual changes and other side effects may discourage US women from using injectable . Fam Plann Perspect. 1996;28: 288-289 .
45.
45. Paul C, Skegg D, Williams S. Depot medroxyprogesterone acetate: patterns of use and reasons for discontinuation . Contraception. 1997;56: 209-214 .
46.
46. Scholes D, La Croix A, Ichikawa L, Narlow W, Ott S. Injectable hormone contraception and bone density: results from a prospective study . Epidemiology. 2002;13: 581-587 .
47.
47. FDA Talk Paper. Update on advisory for Norplant contraceptive kits. Available at: http://www.fda.gov. Accessed November 27, 2002.
48.
48. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon . Contraception. 1998:58: 99S-107S .
49.
49. Makarainen L, van Veek A, Tuomivaara L, Asplund B, Coelingh-Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant . Fertil Steril. 1998;69: 714-721 .
50.
50. Berlex Laboratories, Inc. Mirena Prescribing Information. Montville, NJ: Berlex Laboratories, Inc. ; 2000.
51.
51. Hidalgo M. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years . Contraception. 2002;65: 129-132 .
52.
52. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nov-T . Contraception. 1992;46: 575-584 .
53.
53. Frezieres R, Walsh T, Nelson A, Clark V, Coulson A. Breakage and acceptability of a polyurethane condom: a randomized, controlled study . Fam Plann Perspect. 1998;30: 73-78 .
54.
54. Frezieres R, Walsh T, Nelson A, Clark V, Coulson A. Evaluation of the efficacy of a polyurethane condom: results from a randomized, controlled clinical trial . Fam Plann Perspect. 1999;31: 81-87 .
55.
55. Farr G, Gabelnick H, Sturgen K, Dorflinger L. Contraceptive efficacy and acceptability of the female condom . Am J Publ Health. 1994;84: 1960-1964 .
56.
56. Mauck C, Glover LH, Miller E, et al. Lea's Shield: a study of the safety and efficacy of a new vaginal barrier contraceptive used with and without spermicide . Contraception. 1996;53: 329-335 .
57.
57. Creatsas G, Elsheikh A, Colin P. Safety and tolerability of the new contraceptive sponge Protectaid . Eur J Contracept Reprod Health Care. 2002;7: 91-95 .
58.
58. Creatsas G, Guerrero E, Guilbert E, et al. A multinational evaluation of the efficacy, safety, and acceptability of the Protectaid contraceptive sponge . Eur J Contracept Reprod Health Care. 2001;6: 172-182 .
60. Trussell J, Rodriguez G, Ellertson C. Updated estimates of the effectiveness of the Yuzpe regimen of emergency contraception . Contraception. 1999;59: 147-151 .
61.
61. Trussell J, Rodriguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception . Contraception. 1998;57: 363-369 .
62.
62. Croxatto H, Devoto L, Durand M, et al. Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature . Contraception. 2001;63: 111-121 .
63.
63. Yuzpe A, Lancee W. Ethinylestradiol and dl-norgestrel as a postcoital contraceptive . Fertil Steril. 1977;28: 932-936 .
64.
64. von Hertzen H, Paiggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial . Lancet. 2002;360: 1803-1810 .
65.
65. Raymond E, Creinin M, Barnhart K, Lovvorn A, Rountree W, Trussell J. Meclizine for prevention of nausea associated with use of emergency contraceptive pills: a randomized trial . Obstet Gynecol. 2000;95: 271-277 .
66.
66. Task Force on Postovulatory Methods of Fertility Regulation. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception . Lancet. 1998;352: 428-433 .
67.
67. Trussell J, Ellertson C. Efficacy of emergency contraception . Fertil Control Rev.1995;4: 8-11 .
68.
68. Brown A, Cheng L, Lin S, Baird D. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days . J Clin Endocrinol Metab. 2002;87: 63-70 .
69.
69. Van Damme L, Wright A, Depraetere K, et al. A phase I study of a novel potential intravaginal microbiocide, PRO 2000, in healthy sexually inactive women . Sex Transm Infect. 2000;76: 126-130 .
70.
70. Mauck C, Callahan M, Weiner D, Dominik R. A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm. The FemCap Investigators' Group . Contraception. 1999;60: 71-80 .
71.
71. Amory J, Bremnar W. Newer agents for hormonal contraception in the male . Trends Endocrinol Metab. 2000;11: 61-66 .
72.
72. CONRAD 2000-2001 biennial report. Available at: http://www.conrad.org. Accessed November 26, 2002.
73.
73. Cummings D, Kumar N, Bardin C, Sundaram K, Bremnar W. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception . J Clin Endocrinol Metab. 1998;83: 4212-4219 .
74.
74. Feng H, Sandlow J, Sparks A, Sandra A. Development of an immunocontraceptive vaccine: current status . J Reprod Med. 1999;44: 759-765 .
